logo
The Way You Breathe Could Reveal a Hidden Sign of Alzheimer's

The Way You Breathe Could Reveal a Hidden Sign of Alzheimer's

Yahoo23-02-2025

Earlier, more reliable Alzheimer's disease detection means better post-diagnosis support and more opportunity to understand how it gets started.
Researchers from the UK and Slovenia have now found specific brain activity and breathing patterns can act as signs of Alzheimer's.
The team set out to study how oxygenation of the brain might be linked to neurodegenerative diseases, comparing measures of brain oxygenation, heart rate, brain waves, and breathing effort of 19 Alzheimer's patients to 20 people without Alzheimer's.
Their analysis found differences in neurons linked to blood vessels and in how blood oxygen levels fluctuated as neurons fired. The sync of blood flow and brain activity seems to be noticeably disrupted in Alzheimer's brains.
What's more, there was an unexpected extra: the Alzheimer's patients had a higher breathing rate than the control patients, around 17 breaths per minute compared to 13 breaths per minute. This is possibly a result of changes in how blood vessels in the brain connect with deeper nerve tissues to provide a generous supply of oxygen.
"This is an interesting discovery – in my opinion a revolutionary one – that may open a whole new world in the study of Alzheimer's disease," says biophysicist Aneta Stefanovska, from Lancaster University in the UK.
"It most likely reflects an inflammation, maybe in the brain, that once detected can probably be treated and severe states of Alzheimer's might be prevented in the future."
The setup for the analysis involves a variety of electrical and optical sensors on the scalp – but it doesn't require any blood or tissue samples, and is cheaper and quicker than a lot of other diagnosis options.
And while breathing patterns on their own wouldn't yet be enough to detect Alzheimer's, with so many other variables in play, researchers can now look at respiratory rates in future studies to build up a more complete picture of Alzheimer's symptoms.
This supports the hypothesis that Alzheimer's disease is triggered by a breakdown in the functioning of the brain's vascular system, which reduces the efficiency of oxygen flow and clearance of toxic materials.
"The vascular system and the brain work together to ensure that the brain receives sufficient energy," says neurologist Bernard Meglič, from the University of Ljubljana in Slovenia.
"In fact, the brain needs as much as 20 percent of the body's overall energy consumption despite contributing only about 2 percent of the body's weight."
There's much to consider with Alzheimer's – from symptoms to risk factors – that it's likely that a combination of causes are working in combination, but research like this helps get us closer to understanding the disease's progression.
"We show clear results of our approach and how Alzheimer's can be detected simply, noninvasively, and inexpensively," says Stefanovska.
"The method has great potential, and we are discussing possibilities to create a spin-out or start-up company to proceed with it. Of course, more research is needed."
The research has been published in Brain Communications.
Yogurt Shows Great Potential Against Colon Cancer, Study Reveals
This New Drug Mimics The Health Effects of Living at High Altitude
The Seeds of Schizophrenia May Be Planted in The Earliest Moments of Life

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Tips to take care of your brain for Alzheimer's and Brain Health Awareness Month
Tips to take care of your brain for Alzheimer's and Brain Health Awareness Month

Yahoo

time4 hours ago

  • Yahoo

Tips to take care of your brain for Alzheimer's and Brain Health Awareness Month

June is Alzheimer's and Brain Health Awareness Month and people hoping to spread that awareness said there are things you can do to take charge of your brain health. Brain changes that cause Alzheimer's can begin 20 years or more before symptoms appear. Work to start on Rockdale Road next week Doing things like exercising, eating right, getting good quality sleep, and controlling blood pressure can improve brain health and reduce the risk of cognitive decline. While age and family history are factors, these can naturally help you to reduce your risk. Millcreek man says over $1000 was stolen from EBT account 'It's not just the individual with the diagnosis, but it's the over 480 thousand caregivers here in the state of Pennsylvania that are providing that care. It's the family members that are in that circle of care who need that information and support. We want people to know they're not alone,' said Sara Murphy, vice president of programs and services for the Alzheimer's Association Greater PA Chapter. Early detection of cognitive diseases is crucial. The Alzheimer's Association also has a help line that anyone can call to get support at 1-800-272-3900. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Alpha Cognition Inc. Common Stock (ACOG): A Bull Case Theory
Alpha Cognition Inc. Common Stock (ACOG): A Bull Case Theory

Yahoo

time7 hours ago

  • Yahoo

Alpha Cognition Inc. Common Stock (ACOG): A Bull Case Theory

We came across a bullish thesis on Alpha Cognition Inc. Common Stock (ACOG) by anygal on r/investing on Reddit. In this article, we will summarize the bulls' thesis on ACOG. Alpha Cognition Inc. Common Stock (ACOG)'s share was trading at $9.33 as of 30th May. ACOG's forward P/E was 26.88 according to Yahoo Finance. A chemist in a laboratory analyzing data from the various therapeutic tests conducted. Alpha Cognition Inc. (NASDAQ: ACOG) represents a potentially overlooked opportunity in the Alzheimer's treatment space, having recently launched its oral drug, Zunveyl, at the end of March. With a current market cap of $150 million and $45 million in cash, the company is targeting the underserved segment of the Alzheimer's population—specifically, the 50% of patients in long-term care (LTC) not taking any current medications due to severe side effects. Unlike other galantamine-based drugs, Zunveyl significantly slows disease progression and improves short-term memory with a markedly better safety profile—only one serious side-effect case was reported in its Phase 3 trials, versus a 50% rate seen in traditional options. The drug's Medicare coverage further eases affordability, lowering monthly out-of-pocket costs to $30–$190. Initial demand appears promising, with nearly 500 patients starting treatment in the first two weeks of launch. Even a modest 1% market penetration into the LTC segment could yield $135 million in annual revenue, with $67.5 million in net income assuming 50% margins. A 5% penetration would put net income at $675 million, dwarfing the current valuation. Alpha Cognition has also secured a distribution deal with a major Chinese pharmaceutical firm, creating a royalty-based revenue stream in Asia. While the upside is substantial, key risks remain—most notably, the emergence of unforeseen serious side effects post-launch, which could lead to FDA scrutiny or suspension of sales. Still, the market's underreaction and the company's positioning as a safer, effective alternative in a high-need space make ACOG a high-upside, high-conviction bet for risk-tolerant investors. Previously, we have covered ACOG in March 2025 wherein we summarized a by BullishDoctor on Twitter. The user highlighted that Alpha Cognition Inc.'s drug ZUNVEYL addressed the major side effects of existing Alzheimer's treatments, making it highly tolerable and poised for adoption in long-term care facilities, a $2 billion market. The company was pre-revenue but launched in March 2025 with strong physician support, a nearly complete sales force, and promising catalysts like a Phase 4 study and sublingual formulation, projecting breakeven within three years. Since our last coverage, the stock is up 61% as of 30th May. Alpha Cognition Inc. Common Stock (ACOG) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 8 hedge fund portfolios held ACOG at the end of the first quarter which was 10 in the previous quarter. While we acknowledge the potential of ACOG as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

IVF parents are spending thousands to predict their babies' chances of having Alzheimer's, cancer and heart disease
IVF parents are spending thousands to predict their babies' chances of having Alzheimer's, cancer and heart disease

New York Post

time7 hours ago

  • New York Post

IVF parents are spending thousands to predict their babies' chances of having Alzheimer's, cancer and heart disease

Maybe she's born with it, maybe it's … genetic optimization? Prospective parents using in vitro fertilization (IVF) will soon be able to select embryos based on their potential risk for diseases — including illnesses that develop later in life — thanks to a groundbreaking $5,999 service announced this week by a US biotech company. 'Before there's a heartbeat, there's DNA,' Kian Sadeghi, founder and chief executive of Nucleus Genomics, said in a statement. 'One file containing DNA and genetic markers can tell you more about your baby's future than any other test a doctor could possibly run at this stage.' 4 Supporters say screening could prevent chronic illness, but critics warn it may fuel stigma and inequality. New Africa – What is IVF? The popular fertility treatment involves removing eggs from a woman's ovaries and fertilizing them with sperm in a lab. The resulting embryo — which could be frozen or fresh — is placed into the uterus, where it hopefully implants in the uterine wall and sparks a pregnancy. Before implantation, many IVF clinics already screen embryos for genetic abnormalities — such as extra chromosomes or gene mutations — that can lead to failed implantations, miscarriages, birth defects or inherited disorders. But the first-of-its-kind service from Nucleus Genomics takes things a step further. Build-a-baby The company just launched Nucleus Embryo, a new software platform that lets potential parents dig deep into the full genetic blueprint of their embryos before choosing which one to implant. 4 The number of Americans using IVF has skyrocketed over the last decade. – The tool lets IVF patients compare the DNA of up to 20 embryos, screening them for more than 900 conditions — including Alzheimer's, Type 2 diabetes, heart disease and several forms of cancer. It doesn't stop there. The program also flags potential mental health conditions like depression and schizophrenia and even ranks cognitive traits like IQ. Parents can also get a look at cosmetic and physical features, from height, baldness and BMI to eye and hair color. The company isn't promising perfection. Instead, the software generates a so-called polygenic risk score that will give parents the probability of how likely it is an embryo might develop certain traits or diseases. 4 Many IVF clinics already screen for certain genetic risk factors, like an abnormal number of chromosomes. Charlize Davids/ – Ultimately, it's up to the parents to decide which qualities matter most to them. For those looking to decode the results, genetic counseling sessions are available. 'Lifespan has dramatically increased in the last 150 years,' Sadeghi told the Wall Street Journal. 'DNA testing to predict and reduce chronic disease can make it happen again.' A new era of reproductive tech The practice, known as polygenic embryo screening, is already highly controversial in the medical world, according to a report published by Harvard Law School's Petrie-Flom Center. Critics warn that allowing parents to screen embryos for risks like depression or diabetes could deepen stigma and discrimination against people living with those conditions. Meanwhile, disability advocates argue it promotes the harmful idea that disability is something to be fixed, not a natural part of human diversity. And when it comes to choosing embryos for traits like intelligence or athleticism, critics say we're sliding into designer baby territory — a modern form of eugenics that favors the rich, reinforcing social and healthcare inequalities. 4 Few Americans approve of using the technology to predict traits unrelated to disease. Gemyful – Still, the public appears open to some aspects of the tech. A 2023 survey found that 77% of Americans support using it to screen embryos for the likelihood of developing certain physical conditions, while 72% back screening for mental health risks. Proponents argue it's no different from vaccination — a preventive tool, not a judgment on those with the condition. But when it comes to non-medical traits, support drops fast: only 36% back screening embryos for behavioral traits and just 30% for physical features like height or eye color.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store